8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  March 19, 2007

AFFYMETRIX, INC.

(Exact name of registrant as specified in its charter)

DELAWARE	0-28218	77-0319159
(State of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

3420 Central Expressway

Santa Clara, California 95051

(Address of principal executive offices) (Zip Code)

(408) 731-5000

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

The Board of Directors of Affymetrix, Inc. (“Affymetrix” or the “Company”) elected Robert P. Wayman to serve as a member of the Company’s Board of Directors effective as of March 19, 2007.  In connection with his election to the Company’s Board, Mr. Wayman has been named as a member of the Company’s Audit Committee.  Mr. Wayman retired from Hewlett-Packard Company (“HP”) on December 31, 2006 having served most recently as HP’s Chief Financial Officer since 1984.  Mr. Wayman served as interim CEO of HP from February 2005 through March 2005 and served on the Board of Directors of HP from February 2005 to March 2007 and previously from 1993 to 2002.  Mr. Wayman is also a director of Con-way Inc. and Sybase Inc.  There are no arrangements between Mr. Wayman and any other persons pursuant to which Mr. Wayman was selected as a director.  There are no transactions, or proposed transactions, to which the Company is or was to be a party and in which Mr. Wayman had a direct or indirect material interest that are required to be disclosed under Item 404(a) of Regulation S-K.  A copy of the press release announcing Mr. Wayman’s election is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01Financial Statements and Exhibits

(d)                Exhibits

Exhibit No.	Description
99.1	Press Release dated March 19, 2007

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AFFYMETRIX, INC.
By:	/s/ Barbara A. Caulfield
	Name: Barbara A. Caulfield
	Title: Executive Vice President and General Counsel

Dated: March 20, 2007

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release dated March 19, 2007

EX-99.1

EXHIBIT 99.1

Media Contact:

Wes Conard

Sr. Director, Corporate & Marketing Communications

408-731-5571

Investor Contact:

Doug Farrell

Vice President, Investor Relations

408-731-5285

Affymetrix Appoints Robert Wayman to Board of Directors

SANTA CLARA, Calif., March 19, 2007 — Affymetrix Inc. (Nasdaq: AFFX) announced today that Robert P. Wayman, former executive vice president and chief financial officer at Hewlett-Packard, has been elected to the company’s board of directors.

“We are pleased to add Robert Wayman to the company’s board,” said Stephen P.A. Fodor, Ph.D., chairman and CEO at Affymetrix. “He is a well-respected corporate leader with an impeccable reputation as a financial officer. His insights and experiences will be instrumental as we continue to grow our commercial organization around the world.”

“For the past 15 years, Affymetrix has consistently delivered new products that provide researchers with a more complete view of the genome,” said Wayman. “I look forward to being a part of this innovative organization, which continues to help accelerate scientific research and improve patient care.”

Wayman retired from HP on December 31, 2006, after joining the company in 1969 as a cost accountant. He held a variety of finance positions before being named CFO in 1984. He also served as interim chief executive officer in 2005 prior to the appointment of Mark Hurd. Wayman was elected to the HP board of directors in February 2005 and previously served on the board from 1993 to 2002. Wayman is also a director of Conway Inc. and Sybase Inc.

About Affymetrix

Affymetrix GeneChip® microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases.

Today, Affymetrix technology is used by the world’s top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,500 systems have been shipped around the world and more than 8,500 peer-reviewed papers have been published using the technology.

Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company’s website at www.affymetrix.com.

Forward-looking Statements

All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including the value of Robert Wayman’s experience and expertise to Affymetrix, which is prospective; risks of the company’s ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties relating to technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties relating to sole-source suppliers; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2006, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix’ expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

NOTE: Affymetrix, the Affymetrix logo and GeneChip® are registered trademarks owned or used by Affymetrix Inc.

# # #